Literature DB >> 15095851

Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study.

Virgínia Piñol1, Montserrat Andreu, Antoni Castells, Artemio Payá, Xavier Bessa, Jover Rodrigo.   

Abstract

BACKGROUND: Colorectal cancer is the third leading cause of cancer mortality in Western countries. Hereditary nonpolyposis colorectal cancer is the most common type of hereditary colorectal cancer, but its incidence remains controversial, ranging from 1 to 5%.
OBJECTIVE: This present prospective, multicentre, nationwide study was aimed at compiling prominent epidemiological and clinical data with respect to hereditary non-polyposis colorectal cancer and other familial colorectal cancer forms in Spain, where information is lacking.
METHODS: All patients with a de-novo diagnosis of colorectal cancer and who attended between November 2000 and October 2001 in 25 hospitals all over Spain were registered. Demographic, clinical and tumour-related characteristics of probands, and detailed family history, were obtained.
RESULTS: A total of 1872 colorectal cancer patients were included. Clinical diagnosis of hereditary non-polyposis colorectal cancer was established in 46 (2.5%) patients according to the Amsterdam II criteria. Comparison between patients fulfilling either the Amsterdam I or the Amsterdam II criteria revealed no differences with respect to demographic, clinical and tumour-related characteristics. A total of 504 (27.0%) patients had a family history of hereditary non-polyposis colorectal cancer-related neoplasm not fulfilling the Amsterdam criteria (familial colorectal cancer), while 360 (19.2%) patients fulfilled at least one of the Bethesda's criteria.
CONCLUSION: These clinicoepidemiological data provide a more accurate characterization of hereditary non-polyposis colorectal cancer and other familial colorectal cancer forms in Spain, with potential implications in preventive strategies.

Entities:  

Mesh:

Year:  2004        PMID: 15095851     DOI: 10.1097/00042737-200401000-00007

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  24 in total

1.  MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer.

Authors:  María Dolores Giráldez; Francesc Balaguer; Luis Bujanda; Miriam Cuatrecasas; Jenifer Muñoz; Virginia Alonso-Espinaco; Mikel Larzabal; Anna Petit; Victoria Gonzalo; Teresa Ocaña; Leticia Moreira; José María Enríquez-Navascués; C Richard Boland; Ajay Goel; Antoni Castells; Sergi Castellví-Bel
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

Authors:  Rodrigo Jover; Thuy-Phuong Nguyen; Lucía Pérez-Carbonell; Pedro Zapater; Artemio Payá; Cristina Alenda; Estefanía Rojas; Joaquín Cubiella; Francesc Balaguer; Juan D Morillas; Juan Clofent; Luis Bujanda; Josep M Reñé; Xavier Bessa; Rosa M Xicola; David Nicolás-Pérez; Antoni Castells; Montserrat Andreu; Xavier Llor; C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-12-24       Impact factor: 22.682

3.  Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients.

Authors:  Francesc Balaguer; Judith Balmaña; Sergi Castellví-Bel; Ewout W Steyerberg; Montserrat Andreu; Xavier Llor; Rodrigo Jover; Sapna Syngal; Antoni Castells
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

4.  Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.

Authors:  R Jover; P Zapater; A Castells; X Llor; M Andreu; J Cubiella; V Piñol; R M Xicola; L Bujanda; J M Reñé; J Clofent; X Bessa; J D Morillas; D Nicolás-Pérez; A Payá; C Alenda
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

5.  [Can we be satisfied with a clear colonoscopy? Interval colorectal cancer].

Authors:  Javier Aranda Hernández; Antonio L Aguilar-Shea; José Carlos Marín Gabriel
Journal:  Aten Primaria       Date:  2011-04-15       Impact factor: 1.137

6.  Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome.

Authors:  Lucía Pérez-Carbonell; Cristina Alenda; Artemio Payá; Adela Castillejo; Víctor M Barberá; Carmen Guillén; Estefanía Rojas; Nuria Acame; Francisco J Gutiérrez-Aviñó; Antoni Castells; Xavier Llor; Montserrat Andreu; José-Luis Soto; Rodrigo Jover
Journal:  J Mol Diagn       Date:  2010-05-20       Impact factor: 5.568

7.  Malignant colorectal polyps.

Authors:  Luis Bujanda; Angel Cosme; Ines Gil; Juan I Arenas-Mirave
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

8.  The challenge of colorectal cancer prevention in Spain.

Authors:  Julio Lopez-Bastida; Begoña Bellas-Beceiro; Enrique Quintero-Carrión
Journal:  Eur J Health Econ       Date:  2010-01

9.  A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations.

Authors:  Cristina Martínez-Bouzas; Elena Beristain; Enrique Ojembarrena; Jose Errasti; Karmele Mujika; Noelia Viguera; Maria Isabel Tejada
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

10.  Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer.

Authors:  Victoria Gonzalo; Juan José Lozano; Jenifer Muñoz; Francesc Balaguer; Maria Pellisé; Cristina Rodríguez de Miguel; Montserrat Andreu; Rodrigo Jover; Xavier Llor; M Dolores Giráldez; Teresa Ocaña; Anna Serradesanferm; Virginia Alonso-Espinaco; Mireya Jimeno; Miriam Cuatrecasas; Oriol Sendino; Sergi Castellví-Bel; Antoni Castells
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.